Dana-Farber Cancer Center
Boston, Massachusetts 02215
3 studies enrolling now · 43 studies all time
What they study most
ALK-Positive Lung Cancer, ALK-positive NSCLC, ALK-positive Non-small Cell Lung Cancer, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), Advanced Gastrointestinal Stromal Tumors (GIST), Advanced Malignancies Except Leukemia, Advanced NRAS/BRAFT wt Cutaneous Melanoma, Advanced Solid Tumor, Aphasia
Studies at this site
- A Long-term Extension Study of PCI-32765 (Ibrutinib) — Recruiting now
- A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC — Recruiting now
- A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib — Recruiting now
- Listen Aphasia Pilot Study — Starting soon
- Lifestyle, Exercise, and Nutrition Study Early After Diagnosis — Completed
- Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors — Stopped early
- Peer Support For Young Adult Women With High Breast Cancer Risk — Completed
- Delirium in Children Undergoing Stem Cell Transplantation — Running, not enrolling
- Study of ART0380 in Patients With Biologically Selected Solid Tumors — Stopped early
- Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia — Running, not enrolling
- Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies — Completed
- A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) — Running, not enrolling
- Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs — Completed
- Study of Cabozantinib (XL184) in Adults With Advanced Malignancies — Completed
- Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) — Running, not enrolling
- Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer — Withdrawn before enrolling
- A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer — Completed
- Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease — Completed
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) — Completed
- Study of INCB053914 in Subjects With Advanced Malignancies — Stopped early
- Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies — Completed
- A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer — Completed
- Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis — Stopped early
- Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors — Stopped early
- Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) — Completed
- Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease — Completed
- Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma — Stopped early
- Preoperative Herceptin and Navelbine for Breast Cancer — Completed
- Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer — Completed
- Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy — Completed
- Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer — Status unconfirmed
- Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma — Completed
- A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer — Completed
- Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer — Completed
- Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) — Completed
- Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure — Stopped early
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation — Completed
- A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 — Completed
- PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma — Completed
- Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia — Completed
- Pemetrexed in Patients With Advanced Neuroendocrine Tumors — Completed
- Mantle Irradiation for Hodgkin's Disease — Completed
- Educational Interventions for Patients With DCIS — Completed